Responsibility & ESG

Respecting environmental, social and governance aspects are a central responsibility for Marinomed.

Environment, Social and Governance (ESG) at Marinomed

 

Marinomed is a science-driven company committed to medical progress. It is our vision to alleviate or prevent diseases through continuous research and development. Specifically, our mission is to improve the health of people worldwide and to develop treatments for indications that have no or no adequate treatments so far. In doing so, we are working directly towards Goal 3 of the United Nations Sustainable Development Goals, health for all and well-being for all ages.

Marinomed pursues a highly sustainable business model and has specialised in the research and development of biopharmaceutical products in the therapeutic areas of virology and immunology. After approval (or Declaration of Conformity for medical devices), Marinomed contracts experienced partners via licenses who then produce and distribute these products. Outsourcing these parts of the value chain enables Marinomed to maintain a lean “asset light” business model even when it experiences strong growth. The use of existing production sites and distribution channels helps conserve resources and save costs, keeping the ecological footprint small and thus promoting sustainability.

Sustainable business practices are essential for Marinomed, which is why management is collectively responsible for the planning of strategic development. Important sustainability topics are routinely on the agenda and are regularly addressed by the entire management team and integrated into ongoing projects. The management board firmly believes that long-term economic success can only be achieved if both social and ecological aspects are taken into account. Corporate decisions are made on the basis of this awareness, and processes that are within the Company’s sphere of influence are evaluated at regular intervals in order to continuously increase sustainability in various areas. The supervisory board receives regular reports on the improvement of sustainability.

Marinomed already persecutes a sustainable business model. Our primary goal is to maintain these high standards and raise them even further, wherever possible. This is especially true for our research and development activities and our products. We make a lasting contribution to healthcare. An effective healthcare system with drugs and medical products that can alleviate or heal diseases is in the interests of society as a whole because it affects us all. This is why dialogue with all stakeholders is essential to help us make our contribution to a sustainable future. We will keep having more of these conversations. Our efforts in this regard include reporting that provides wide-ranging information about our sustainability ambitions and achievements. You can find detailed information in our sustainability report:

 

Marinomeds ESG strategy

ESG Highlights 2021

ENVIRONMENT

New Company Headquarter in Korneuburg, AT

SDG 13, 15
  • Removal of the sealed surface and added greening to the property
  • Thermal renovation of existing buildings
  • Environmentally friendly new building and usage of renewable energies
  • Fleet almost fully electric

SOCIAL

Marinosolv Solubilisation Technology

SDG 3, 9, 17
  • Solv4U for technology partnerships
  • First partnership for Budesolv
  • R&D advances (Indications with high medical need)

Employees & Diversity

SDG 5, 8
  • Employee growth +16%
  • Investor relations strengthened
  • High diversity: again 1st place in the BCG Gender Diversity Index

Virusblocker Carragelose

SDG 3, 9, 17
  • Sales +20%

  • New partnerships for global availability

  • Efficacy proven against SARS-CoV-2 variants of concern

  • Support of the Vienna City Marathon

GOVERNANCE

Employees

SDG 4, 8
  • Expansion of quality and training management
  • Re-evaluation of principles of the Corporate Governance Codex
  • Increased evaluation of sustainable corporate goals

Corporate Governance

Marinomed is committed to the guidelines of the Austrian Corporate Governance Code in the version of January 2018 and complies with all provisions required by law (L-Rules) and to a large extent with the provisions required by the Code (C-Rules). C-Rules that have not yet been fully complied with are consistently reviewed and their treatment explained in the Corporate Governance Report.

Directors’ Dealings:

15.12.2021 - Dr. Brigitte Ederer / Member of an administrative or supervisory board
(76 KB)
02.12.2021 - Pascal Schmidt / CFO
(187 KB)
02.12.2021 - Eva Prieschl-Grassauer / CSO
(187 KB)
02.12.2021 - Andreas Grassauer / CEO
(187 KB)
16.12.2020 - Eva Prieschl-Grassauer / CSO
(732 KB)
27.01.2020 - Dr. Brigitte Ederer / Member of an administrative or supervisory board
(301 KB)
16.12.2020 - Andreas Grassauer / CEO
(733 KB)
16.12.2020 - Pascal Schmidt / CFO
(732 KB)
20.02.2019 - Ute Lassnig / Member of an administrative or supervisory board
(305 KB)
20.02.2019 - Simon Nebel / Chairman of the supervisory board
(304 KB)
18.10.2019 - Mag.(FH) Karl Lankmayr / Member of an administrative or supervisory board
(304 KB)
30.01.2019 - Ute Lassnig / Member of an administrative or supervisory board
(22 KB)
31.01.2019 - Simon Nebel / Chairman of the supervisory board
(42 KB)
01.02.2019 - Mag.(FH) Karl Lankmayr / Member of an administrative or supervisory board
(43 KB)
01.02.2019 - Dr. Gernot Hofer / Member of an administrative or supervisory board
(43 KB)
18.10.2019 - Dr. Gernot Hofer / Member of an administrative or supervisory board
(303 KB)
Stephanie Kniep, Dipl.-Ök.
Head of Investor Relations
Marinomed Biotech AG
Hovengasse 25
2100 Korneuburg, Austria
+43 2262 90300
office@marinomed.com